- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02178566
Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso
Pulmonary Rehabilitation in COPD: Response to Inhaled Treprostinil (Tyvaso)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Hypothesis:
Our hypothesis is that pre-treating patients with COPD with inhaled treprostinil prior to pulmonary rehabilitation sessions will result in improved exercise tolerance during sessions. This in turn will lead to an increased response to pulmonary rehabilitation, resulting in improved exercise tolerance and quality of life.
Study Background:
Pulmonary rehabilitation (PR) is a widely accepted intervention in patients with advanced COPD. This has consistently been shown to improve patients' quality of life and functional ability. Indeed, enrollment and completion of a course of PR is a prerequisite prior to major interventions such as lung volume reduction surgery or transplantation. A typical course of PR includes 20 sessions of supervised exercise and educational activity over an 8 week period. Sessions are usually held three times per week and last between 2-3 hours each. Most patients with COPD will have a ventilatory limitation to exercise and while many are oxygen dependent, a minority of patients will have a true hypoxic limitation to exercise. Nonetheless, when patients with COPD are ambulated on oxygen they feel better and walk further. Indeed, supplemental oxygen remains one of the few interventions that have been demonstrated to be associated with improved survival in patients with COPD.
There have been a few studies and case reports utilizing inhaled pulmonary vasodilators in patients with COPD, although none to date have used treprostinil. One study of 10 patients with COPD and pulmonary hypertension found improved gas exchange and exercise tolerance following using of inhaled iloprost an alternative inhaled pulmonary vasodilator. No adverse effects were observed. [Dernaika TA, Beavin M, Kinasewitz GT. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration; 2010: 79(5): 377-382.)] A case report of a patient with pulmonary hypertension and COPD found sustained improvements in exercise tolerance with regular use of inhaled iloprost. [Hegewald MJ, Elliott CG. Sustained improvement with iloprost in a COPD patient with severe pulmonary hypertension. Chest 2009; 135(2): 536-537.] While these limited trials support the concept of physiologic improvement with use of inhaled pulmonary vasodilators in COPD, our study differs from these in several important ways. This study is unique in that there has never been a prior similar study of medication pretreatment prior to PR to enhance exercise performance in any patient subgroup. Furthermore, treprostinil has not yet been evaluated for use on an as needed basis.
Indication Studied:
COPD/Pulmonary rehabilitation
Study Objectives:
- Primary Objective: To determine the effect of inhaled treprostinil, administered prior to pulmonary rehabilitation sessions, on the six minute walk test distance (6MWT) in COPD patients after completing an 8 week course of pulmonary rehabilitation
- Secondary Objectives: To assess the effect inhaled treprostinil, administered prior to pulmonary rehabilitation in COPD patients, on secondary outcomes including quality of life (as measured by the St. George's respiratory questionnaire, Clinical COPD Questionaire), BODE index, lowest nadir of oxygen saturation on 6 minute walk test, number of exacerbations, ER visits, hospitalizations, and change in measures of strength training.
Trial Design:
An adaptive, prospective, randomized, double-blind, placebo-controlled study of 34 patients with advanced COPD who have been referred for pulmonary rehabilitation. All patients will be screened at baseline with an arterial blood gas. A test dose of inhaled nitric oxide (NO) will be administered to all subjects for 2-5 minutes. An ABG will then be repeated. Patients who have a worsened A-a gradient will be screened out. Patients will be randomized to receive one dose of inhaled treprostinil or placebo prior to each of their exercise sessions. All patients will be pretreated with albuterol prior to the dose of inhaled treprostinil (or placebo).
Patient Population:
We plan to screen 50 patients with a goal of enrolling 34 patients. Patients referred for pulmonary rehabilitation at Inova Fairfax Hospital with moderate to severe COPD as a primary diagnosis will be screened for inclusion in the trial. Inclusion and exclusion criteria are listed below.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Virginia
-
Falls Church, Virginia, United States, 22042
- Inova Fairfax Medical Campus
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing to sign informed consent prior to initiation of any study mandated procedure
- Male or female ≥ 40 years of age
- Women of childbearing potential must use a reliable method of contraception from screening until 1 month after end of study medication
Clinical diagnosis of moderate to severe COPD, with an obstructive pattern on pulmonary function tests showing both:
- FEV1/FVC < 0.7 and
- FEV1 ≤ 60% of predicted value, on standard COPD therapy
- Current or past smokers of ≥ 10 pack years
- If taking oral (< 20 mg/day of prednisone equivalent) or inhaled corticosteroids, inhaled beta-agonists (short and long acting), or inhaled muscarinic antagonists (short and long acting), or statins the dose must be stable for at least 30 days prior to initial PR visit.
- Ability to adequately participate in exercise testing/pulmonary rehabilitation program with supplemental oxygen use over the period of the study (in the best opinion of the investigator)
Exclusion Criteria:
Patients fulfilling one or more of the following criteria of documented COPD exacerbation within 1 months prior to screening:
- Use of antibiotics for COPD exacerbation
- Initiation or dose increase of steroids (inhaled, oral or intravenous) for COPD exacerbation
- Hospitalization for COPD exacerbation
- BMI > 40 kg/m2
- Unstable coronary artery disease, unstable angina, or myocardial infarction within 3 months prior to screening
- History of pulmonary edema, or uncontrolled heart failure
- Uncontrolled systemic hypertension with a blood pressure >180/105 mmHg at rest
- Systemic hypotension with systolic blood pressure < 85 mmHg
- Uncontrolled arrhythmias
- History of syncope
- Planned surgical intervention during the study period
- Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results including musculo-skeletal limitations, peripheral arterial disease, drug or alcohol dependence or psychiatric disease
- Severe hepatic impairment (Child-Pugh Class C)
- Chronic renal insufficiency, as defined by serum creatinine of > 2.5 mg/dL or estimated creatinine clearance < 30 mL/min or the requirement for dialysis
- Pregnant or nursing
- Currently (within 30 days prior to enrollment) taking specific pulmonary arterial hypertension therapy (e.g., bosentan, ambrisentan, tadalafil, sildenafil, epoprostenol, treprostinil, iloprost, beraprost), sildenafil and tadalafil for erectile dysfunction is permitted
- Initiation of a pulmonary rehabilitation program within 3 months prior to screening or initiation or changes during the study
- Participation in any other clinical trial, except observational, or receipt of an investigational medicinal product within 30 days prior to RHC visit
- Known concomitant life-threatening disease with a life expectancy < 6 months
- Known hypersensitivity to treprostinil or any of the excipients of the drug formulations.
- Known hypersensitivity to inhaled nitric oxide
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Inhaled Treprostinil Placebo
A dose of placebo resembling inhaled treprostinil will be administered to all study participants in the placebo comparator arm prior to each of their Pulmonary Rehab sessions.
A dose of inhaled albuterol will be administered prior to each inhaled agent.
Vitals signs will be taken prior to administering the dose and no medication will be given if the systolic blood pressure in < 85 mm Hg.
Three puffs of inhaled trepostinil dose will be administered each time to all patients .
|
A dose of inhaled treprostinil or placebo will be administered to all study participants prior to each of their Pulmonary Rehab sessions.
Three puffs of inhaled treprostinil dose will be administered each time to all patients .
Other Names:
|
Active Comparator: Inhaled Treprostinil
A dose of inhaled treprostinil will be administered to all study participants prior to each of their Pulmonary Rehab sessions.
A dose of inhaled albuterol will be administered prior to each inhaled agent.
Vitals signs will be taken prior to administering the dose and no medication will be given if the systolic blood pressure in < 85 mm Hg.
Three puffs of inhaled treprostinil dose will be administered each time to all patients .
|
A dose of inhaled treprostinil or placebo will be administered to all study participants prior to each of their Pulmonary Rehab sessions.
Three puffs of inhaled treprostinil dose will be administered each time to all patients .
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Distance Walked on 6MWT
Time Frame: 9 weeks
|
To determine the effect of inhaled treprostinil, administered prior to pulmonary rehabilitation sessions, on the six minute walk test distance (6MWT) in COPD patients after completing an 8 week course of pulmonary rehabilitation
|
9 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Steven Nathan, MD, Inova Fairfax Medical Campus
- Principal Investigator: Christopher King, MD, Inova Fairfax Medical Campus
Publications and helpful links
General Publications
- Dernaika TA, Beavin M, Kinasewitz GT. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration. 2010;79(5):377-82. doi: 10.1159/000242498. Epub 2009 Sep 25.
- Hegewald MJ, Elliott CG. Sustained improvement with iloprost in a COPD patient with severe pulmonary hypertension. Chest. 2009 Feb;135(2):536-537. doi: 10.1378/chest.08-1515.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Inova-TY-PR-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD)
-
University College, LondonUniversity of Cambridge; National Institute for Health Research, United Kingdom and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Reham Mohammed ElmorshedyCompletedChronic Obstructive Pulmonary Disease(COPD)Egypt
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Virginia Commonwealth UniversityFisher and Paykel HealthcareCompletedChronic Obstructive Pulmonary Disease(COPD)United States
-
Beaumont HospitalAerogenCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | Copd Exacerbation AcuteIreland
-
Medtronic BRCUnknownCOPD | COPD Exacerbation
-
Chiesi Farmaceutici S.p.A.CompletedModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
-
Chiesi Farmaceutici S.p.A.CompletedChronic Obstructive Pulmonary Disease (COPD) | COPDUnited Kingdom
-
Elpen Pharmaceutical Co. Inc.Completed
-
Aalborg UniversityCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | COPD Exacerbation AcuteDenmark
Clinical Trials on Inhaled Treprostinil
-
Liquidia Technologies, Inc.Nuventra, Inc.CompletedPrimary Pulmonary HypertensionUnited States
-
Liquidia Technologies, Inc.Nuventra, Inc.Active, not recruitingPrimary Pulmonary HypertensionUnited States
-
Liquidia Technologies, Inc.FGK Clinical Research GmbHTerminatedPulmonary Arterial HypertensionFrance, Germany
-
United TherapeuticsTerminatedPulmonary Hypertension | Interstitial Lung Disease | Combined Pulmonary Fibrosis and EmphysemaUnited States, Puerto Rico
-
United TherapeuticsWithdrawnPulmonary Arterial Hypertension
-
United TherapeuticsRecruitingIdiopathic Pulmonary Fibrosis | Interstitial Lung DiseaseTaiwan, Belgium, Spain, Korea, Republic of, Germany, Australia, Chile, Denmark, France, Mexico, Israel, Italy, Netherlands, Argentina, New Zealand, Peru
-
United TherapeuticsEnrolling by invitationIdiopathic Pulmonary Fibrosis | Interstitial Lung DiseaseUnited States, Spain, Australia, Taiwan, Israel, Korea, Republic of, Belgium, France, Argentina, Chile, Denmark, Mexico
-
Ferrer Internacional S.A.AvailablePulmonary Hypertension | Interstitial Lung Disease | Combined Pulmonary Fibrosis and Emphysema
-
Insmed IncorporatedCompleted
-
United TherapeuticsLung Biotechnology PBCTerminatedChronic Obstructive Pulmonary Disease | Pulmonary HypertensionUnited States, Israel